摘要：【中文】甾体类衍生物FXR激动剂（式I）的结晶或无定型物、及其制备方法，包含该结晶或无定型物的结晶组合物、药物组合物，以及它们在制备治疗或预防FXR相关各种病症的药物中的用途。 【EN】Steroid derivative FXR agonist (formula I) crystal or amorphous substance, preparation method thereof, crystal composition containing the crystal or amorphous substance, pharmaceutical composition containing the crystal or amorphous substance, and application of the crystal or amorphous substance in preparation of medicines for treating or preventing FXR related diseasesUse in the manufacture of a medicament for a disorder.

摘要：【中文】属于药物化学领域，涉及甾体类衍生物FXR激动剂的制备方法及相关中间体。具体而言，涉及一种制备式I化合物的方法，其包括使式8化合物和式9化合物反应以获得式10化合物，从式10化合物反应以获得式11化合物，从式11化合物反应以获得式I化合物，以及所用中间体、中间体的制备方法和中间体的用途。该制备方法反应条件温和，部分步骤可以同时转变多个基团，有效缩短步骤，适合工业化生产。(I) 【EN】Belongs to the field of pharmaceutical chemistry, and relates to a preparation method of a steroid derivative FXR agonist and a related intermediate. In particular, it relates to a process for the preparation of a compound of formula I comprising reacting a compound of formula 8 with a compound of formula 9 to obtain a compound of formula 10, reacting from a compound of formula 10 to obtain a compound of formula 11, reacting from a compound of formula 11 to obtain a compound of formula I, as well as intermediates used, processes for the preparation of intermediates and uses of intermediates. The preparation method has mild reaction conditions, can simultaneously convert a plurality of groups in part of steps, effectively shortens the steps, and is suitable for industrial production. (I)

摘要：【中文】一类新的作为EGFR激酶抑制剂的芳基磷氧化合物，其为式(I)所示化合物及其药学上可接受的盐。(I) 【EN】A novel aryl phosphorus oxide compound used as an EGFR kinase inhibitor is a compound shown in a formula (I) and pharmaceutically acceptable salts thereof. (I)

摘要：【中文】本发明涉及作为TLR7激动剂的吡咯并嘧啶化合物，具体涉及式(I)化合物或其药学上可接受的盐、其制备方法、含有该类化合物的药物组合物、及其用于制备抗病毒药物的用途。 【EN】The invention relates to a pyrrolopyrimidine compound serving as a TLR7 agonist, in particular to a compound shown as a formula (I) or a pharmaceutically acceptable salt thereof, a preparation method thereof, a pharmaceutical composition containing the compound and application thereof in preparing antiviral drugs.

摘要：【中文】本发明涉及喹啉衍生物用于治疗肿瘤的方法和用途以及用于治疗肿瘤的药物组合物。具体而言，本发明涉及喹啉衍生物1‑[[[4‑(4‑氟‑2‑甲基‑1H‑吲哚‑5‑基)氧基‑6‑甲氧基喹啉‑7‑基]氧基]甲基]环丙胺用于治疗软组织肉瘤的方法和用途以及用于治疗软组织肉瘤的药物组合物。 【EN】The invention relates to a method and application of quinoline derivatives for treating tumors and a pharmaceutical composition for treating tumors. In particular, the present invention relates to the method and use of quinoline derivative 1- [ [ [4- (4-fluoro-2-methyl-1H-indol-5-yl) oxy-6-methoxyquinolin-7-yl ] oxy ] methyl ] cyclopropylamine for the treatment of soft tissue sarcoma and to pharmaceutical compositions for the treatment of soft tissue sarcoma.

摘要：【中文】本发明涉及喹啉衍生物用于治疗甲状腺癌的方法和用途，以及用于治疗甲状腺癌的药物组合物。具体而言，本发明涉及喹啉衍生物1‑[[[4‑(4‑氟‑2‑甲基‑1H‑吲哚‑5‑基)氧基‑6‑甲氧基喹啉‑7‑基]氧基]甲基]环丙胺用于治疗甲状腺癌的方法和用途以及用于治疗甲状腺癌的药物组合物。 【EN】The invention relates to methods and uses of quinoline derivatives for the treatment of thyroid cancer, as well as pharmaceutical compositions for the treatment of thyroid cancer. In particular, the present invention relates to the quinoline derivative 1- [ [ [4- (4-fluoro-2-methyl-1H-indol-5-yl) oxy-6-methoxyquinolin-7-yl ] oxy ] methyl ] cyclopropylamine, to methods and uses for the treatment of thyroid cancer and to pharmaceutical compositions for the treatment of thyroid cancer.

摘要：【中文】本发明涉及喹啉衍生物用于治疗肿瘤的方法和用途以及用于治疗肿瘤的药物组合物。具体而言，本发明涉及喹啉衍生物1‑[[[4‑(4‑氟‑2‑甲基‑1H‑吲哚‑5‑基)氧基‑6‑甲氧基喹啉‑7‑基]氧基]甲基]环丙胺用于治疗软组织肉瘤的方法和用途以及用于治疗软组织肉瘤的药物组合物。 【EN】The invention relates to a method and application of quinoline derivatives for treating tumors and a pharmaceutical composition for treating tumors. In particular, the present invention relates to the method and use of quinoline derivative 1- [ [ [4- (4-fluoro-2-methyl-1H-indol-5-yl) oxy-6-methoxyquinolin-7-yl ] oxy ] methyl ] cyclopropylamine for the treatment of soft tissue sarcoma and to pharmaceutical compositions for the treatment of soft tissue sarcoma.

摘要：【中文】本发明涉及喹啉衍生物用于治疗甲状腺癌的方法和用途，以及用于治疗甲状腺癌的药物组合物。具体而言，本发明涉及喹啉衍生物1‑[[[4‑(4‑氟‑2‑甲基‑1H‑吲哚‑5‑基)氧基‑6‑甲氧基喹啉‑7‑基]氧基]甲基]环丙胺用于治疗甲状腺癌的方法和用途以及用于治疗甲状腺癌的药物组合物。 【EN】The invention relates to methods and uses of quinoline derivatives for the treatment of thyroid cancer, as well as pharmaceutical compositions for the treatment of thyroid cancer. In particular, the present invention relates to the quinoline derivative 1- [ [ [4- (4-fluoro-2-methyl-1H-indol-5-yl) oxy-6-methoxyquinolin-7-yl ] oxy ] methyl ] cyclopropylamine, to methods and uses for the treatment of thyroid cancer and to pharmaceutical compositions for the treatment of thyroid cancer.

摘要：【中文】本发明属于化学制药领域，涉及替诺福韦酯有关物质及其制备方法和检测方法。本发明公开了一种如式Ⅲ所示的替诺福韦酯的杂质以及其制备方法，此外，本发明还提供了该杂质的检测方法，对替诺福韦酯的含量分析和质量控制具有重要作用。 【EN】The invention belongs to the field of chemical pharmacy, and relates to a tenofovir disoproxil related substance, a preparation method and a detection method thereof. The invention discloses an impurity of tenofovir disoproxil shown in a formula III and a preparation method thereof, and in addition, the invention also provides a detection method of the impurity, which has important effects on the content analysis and quality control of tenofovir disoproxil.

摘要：【中文】本申请属于药物化学领域，涉及一种胆酸类化合物的制备方法。具体而言，本申请提供了一种如式I所示化合物的制备方法，包括使式2化合物发生氧化反应得到式3化合物，式3化合物连接三甲基硅烷基得式4化合物，式4化合物与乙醛反应得式5化合物，式5化合物发生催化氢化反应得式6化合物，式6化合物的氰基转变为羧基得到式I化合物。该制备方法收率高，所需纯化操作少，适合工业化应用。 【EN】The application belongs to the field of pharmaceutical chemistry, and relates to a preparation method of a cholic acid compound. Specifically, the application provides a preparation method of a compound shown as a formula I, which comprises the steps of carrying out oxidation reaction on a compound shown as a formula 2 to obtain a compound shown as a formula 3, connecting a trimethylsilyl group to the compound shown as the formula 3 to obtain a compound shown as a formula 4, reacting the compound shown as the formula 4 with acetaldehyde to obtain a compound shown as a formula 5, carrying out catalytic hydrogenation reaction on the compound shown as the formula 5 to obtain a compound shown as a formula 6, and converting a cyano group of the compound shown as the formula 6 into a carboxyl group to obtain. The preparation method has high yield and less required purification operation, and is suitable for industrial application.